
MITO
Healthcare · Biotechnology · $23.5M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2022
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 1, 2023 | Time not confirmed | -0.01 | 0.00 | +100.0% |
| Nov 21, 2022 | Time not confirmed | -0.01 | 0.00 | +100.0% |
| Aug 17, 2022 | Time not confirmed | -0.02 | -0.03 | -50.0% |
| Apr 7, 2022 | After the close | -0.08 | -0.03 | +62.5% |
| Nov 11, 2021 | Before the open | -0.02 | -0.01 | +50.0% |
| Aug 5, 2021 | Before the open | -0.02 | -0.03 | -50.0% |
| Apr 6, 2021 | Before the open | 0.01 | -0.03 | -400.0% |
| Nov 5, 2020 | Before the open | -0.02 | -0.02 | 0.0% |
| Aug 6, 2020 | Before the open | -0.02 | -0.02 | 0.0% |
| Apr 1, 2020 | Before the open | -0.02 | 0.02 | +200.0% |
| Nov 14, 2019 | Before the open | -0.04 | -0.04 | 0.0% |
| Aug 14, 2019 | After the close | -0.08 | -0.04 | +50.0% |
| Apr 4, 2019 | After the close | -0.35 | -0.20 |
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's…
| +42.9% |